Nonalcoholic fatty liver disease as a pro-resolution defective disorder

Nutrition

Volumn 29, Issue 1, 2013, Pages 345-349

  Das, Undurti N ^a,b,c  

^a UND LIFE SCIENCES   (United States)

^b JAWAHARLAL NEHRU TECHNOLOGICAL UNIVERSITY   (India)

^c GAYATRI VIDYA PARISHAD COLLEGE OF ENGINEERING   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; CD59 ANTIGEN; GLUCOSE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; LIPOXIN; OMEGA 3 FATTY ACID; PHOSPHOLIPASE A2; POLYUNSATURATED FATTY ACID; PROSTAGLANDIN E2; RESOLVIN; STRESS ACTIVATED PROTEIN KINASE; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; UNCLASSIFIED DRUG;

ARTICLE; BODY MASS; DIET SUPPLEMENTATION; DISEASE ASSOCIATION; DISEASE MARKER; ENDOPLASMIC RETICULUM STRESS; FATTY LIVER; GLUCOSE BLOOD LEVEL; HUMAN; HYPERINSULINEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; METABOLIC SYNDROME X; MOLECULAR PATHOLOGY; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; OXIDATIVE STRESS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN FOLDING; WAIST CIRCUMFERENCE;

ANIMALS; ANTIGENS, CD59; BIOLOGICAL MARKERS; CYTOKINES; FATTY ACIDS, UNSATURATED; FATTY LIVER; HUMANS; INSULIN RESISTANCE; LIPIDS; LIPOXINS; MODELS, BIOLOGICAL; PROGNOSIS;

EID: 84870788078     PISSN: 08999007     EISSN: 18731244     Source Type: Journal    
DOI: 10.1016/j.nut.2012.03.006     Document Type: Article

References (42)

1. Meigs J.B. Insulin resistance syndrome? Syndrome X? Multiple metabolic syndrome? A syndrome at all? Factor analysis reveals patterns in the fabric of correlated metabolic risk factors. Am J Epidemiol 2000, 152:908-911.
2. Marchesini G., Bugianesi E., Forlani G., Cerrelli F., Lenzi M., Manini R., et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003, 37:917-923.
3. Cohen J.C., Horton J.D., Hobbs H.H. Human fatty liver disease: Old questions and new insights. Science 2011, 332:1519-1523.
4. Marchesini G., Brizi M., Morselli-Labate A.M., Bianchi G., Bugianesi E., McCullough A.J., et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999, 107:450-455.
5. Angelico F., Del Ben M., Conti R., Francioso S., Feole K., Fiorello S., et al. Insulin resistance, the metabolic syndrome, and nonalcoholic fatty liver disease. J Clin Endocrinol Metab 2005, 90:1578-1582.
6. Alisi A., Nobili V. Nonalcoholic fatty liver disease in children now: lifestyle changes and pharmacological treatments. Nutrition 2012, 722-726.
7. Adams L.A., Angulo P. Recent concepts in non-alcoholic fatty liver disease. Diabet Med 2005, 22:1129-1133.
8. Bayard M., Holt J., Boroughs E. Nonalcoholic fatty liver disease. Am Fam Physician 2006, 73:1961-1968.
9. Hebbard L., George J. Animal models of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 2011, 8:35-44.
10. Semple R.K., Sleigh A., Murgatroyd P.R., Adams C.A., Bluck L., Jackson S., et al. Postreceptor insulin resistance contributes to human dyslipidemia and hepatic steatosis. J Clin Invest 2009, 119:315-322.
11. Tilg H. The role of cytokines in non-alcoholic fatty liver disease. Dig Dis 2010, 28:179-185.
12. Hotamisligil G.S. Endoplasmic reticulum stress and the inflammatory basis of metabolic disease. Cell 2010, 140:900-917.
13. Crespo J., Cayon A., Fernandez-Gil P., Hernandez-Guerra M., Mayorga M., Domínguez-Díez A., et al. Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology 2001, 34:1158-1163.
14. Bahcecioglu I.H., Yalniz M., Ataseven H., Ilhan N., Ozercan I.H., Seckin D., et al. Levels of serum hyaluronic acid, TNF-alpha and IL-8 in patients with nonalcoholic steatohepatitis. Hepatogastroenterology 2005, 52:1549-1553.
15. Mas E., Danjoux M., Garcia V., Carpentier S., Se'gui B., Levade T., et al. IL-6 deficiency attenuates murine diet-induced non-alcoholic steatohepatitis. PLoS ONE 2009, 4(11):e7929.
16. Memon R.A., Grunfeld C., Feingold K.R. TNF-alpha is not the cause of fatty liver disease in obese diabetic mice. Nat Med 2001, 7:2-3.
17. Deng Q.G., She H., Cheng J.H., French S.W., Koop D.R., Xiong S., et al. Steatohepatitis induced by intragastric overfeeding in mice. Hepatology 2005, 42:905-914.
18. Ii H., Hatakeyama S., Tsutsumi K., Sato T., Akiba S. Group IVA phospholipase A2 is associated with the storage of lipids in adipose tissue and liver. Prostaglandins Other Lipid Mediat 2008, 86:12-17.
19. Pe'rez S., Aspichueta P., Ochoa B., Chico Y. The 2-series prostaglandins suppress VLDL secretion in an inflammatory condition-dependent manner in primary rat hepatocytes. Biochim Biophys Acta 2006, 176:160-171.
20. Enomoto N., Ikejima K., Yamashina S., Enomoto A., Nishiura T., Nishimura T., et al. Kupffer cell-derived prostaglandin E2 is involved in alcohol-induced fat accumulation in rat liver. Am J Physiol Gastrointest Liver Physiol 2000, 279:G100-G106.
21. Ii H., Yokoyama N., Yoshida S., Tsutsumi K., Hatakeyama S., Sato T., et al. Alleviation of high-fat diet-induced fatty liver damage in group IVA phospholipase A2-knockout mice. PLoS One 2009, 4:e8089.
22. Das U.N. A defect in the activities of Δ6 and Δ5 desaturases and proresolution bioactive lipids in the pathobiology of nonalcoholic fatty liver disease. World J Diabetes 2011, 2:176-188.
23. Carmiel-Haggai M., Cederbaum A.I., Nieto N. A high-fat diet leads to the progression of non-alcoholic fatty liver disease in obese rats. FASEB J 2005, 19:136-138.
24. Alwayn I.P.J., Gura K., Nose V., Zausche B., Javid P., Garza J., et al. Omega-3 fatty acid supplementation prevents hepatic steatosis in a murine model of nonalcoholic fatty liver disease. Pediatr Res 2005, 57:445-452.
25. Araya J., Rodrigo R., Videla L.A., Thielemann L., Orellana M., Pettinelli P., et al. Increase in long-chain polyunsaturated fatty acid n-6/n-3 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease. Clin Sci 2004, 106:635-643.
26. Van Aerde J.E., Duerksen D.R., Gramlich L., Meddings J.B., Chan G., Thomson A.B., et al. Intravenous fish oil emulsion attenuates total parenteral nutrition-induced cholestasis in newborn piglets. Pediatr Res 1999, 45:202-208.
27. Yeh S.L., Chang K.Y., Huang P.C., Chen W.J. Effects of n-3 and n-6 fatty acids on plasma eicosanoids and liver antioxidant enzymes in rats receiving total parenteral nutrition. Nutrition 1997, 13:32-36.
28. Sekiya M., Yahagi N., Matsuzaka T., Najima Y., Nakakuki M., Nagai R., et al. Polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREBP-1 suppression. Hepatology 2003, 38:1529-1539.
29. Das U.N. Metabolic syndrome pathophysiology 2010, Wiley-Blackwell, Ames, IO.
30. Hatzitolios A., Savopoulos C., Lazaraki G., Sidiropoulos I., Haritanti P., Lefkopoulos A., et al. Efficacy of omega-3 fatty acids, atorvastatin and orlistat in non-alcoholic fatty liver disease with dyslipidemia. Indian J Gastroenterol 2004, 23:131-134.
31. Das U.N. Molecular basis of health and disease 2011, Springer, New York.
32. Puri P., Baillie R.A., Wiest M.M., Mirshahi F., Choudhury J., Cheung O., Sargeant C., et al. A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology 2007, 46:1081-1090.
33. Gonzalez-Periz A., Horrillo R., Ferre N., Gronert K., Dong B., Moran-Salvador E., et al. Obesity-induced insulin resistance and hepatic steatosis are alleviated by ω-3 fatty acids: a role for resolvins and protectins. FASEB J 2009, 23:1946-1957.
34. Das U.N. Essential fatty acids-a review. Curr Pharm Biotechnol 2006, 7:467-482.
35. Das U.N. Essential fatty acids: Biochemistry, physiology, and pathology. Biotechnology J 2006, 1:420-439.
36. Gangemi S., Luciotti G., D'Urbano E., Mallamace A., Santoro D., Bellinghieri G., et al. Physical exercise increases urinary excretion of lipoxin A4 and related compounds. J Appl Physiol 2003, 94:2237-2240.
37. Festa A., D'Agostino R., Howard G., Mykkänen L., Tracy R.P., Haffner S.M. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000, 102:42-47.
38. Temelkova-Kurktschiev T., Siegert G., Bergmann S., Henkel E., Koehler C., Jaross W., et al. Subclinical inflammation is strongly related to insulin resistance but not to impaired insulin secretion in a high risk population for diabetes. Metabolism 2002, 51:743-749.
39. Das U.N. Is obesity an inflammatory condition?. Nutrition 2001, 17:953-966.
40. Das U.N. Is metabolic syndrome X an inflammatory condition?. Exp Biol Med (Maywood) 2002, 227:989-997.
41. Tamakoshi K., Yatsuya H., Kondo T., Hori Y., Ishikawa M., Zhang H., et al. The metabolic syndrome is associated with elevated circulating C-reactive protein in healthy reference range, a systemic low-grade inflammatory state. Int J Obes Relat Metab Disord 2003, 27:443-449.
42. Bastard J.P., Maachi M., Lagathu C., Kim M.J., Caron M., Vidal H., et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw 2006, 17:4-12.